A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies  by Pellett, Sabine et al.
FEBS Letters 581 (2007) 4803–4808A neuronal cell-based botulinum neurotoxin assay for highly sensitive
and speciﬁc detection of neutralizing serum antibodies
Sabine Pelletta, William H. Teppa, Colin M. Clancya, Gary E. Borodicb, Eric A. Johnsona,*
a Food Research Institute, Department of Bacteriology, University of Wisconsin, Madison, WI 53706, United States
b Department of Ophthalmology, Harvard Medical School, Ocular Plastic and Reconstructive Surgery Division, 5 Cambridge Center,
8th Floor, Cambridge, MA, United States
Received 7 August 2007; revised 29 August 2007; accepted 31 August 2007
Available online 12 September 2007
Edited by Maurice MontalAbstract Clostridium botulinum neurotoxin (BoNT) serotypes
A and B are widely used as pharmaceuticals to treat various neu-
rological disorders and in cosmetic applications. The major
adverse eﬀect of these treatments has been resistance to treat-
ment after multiple injections. Currently, patients receiving
BoNT therapies and patients enrolled in clinical trials for new
applications and/or new formulations of BoNTs are not routinely
monitored for the formation of neutralizing antibodies, since no
assay other than the mouse protection procedure is commercially
available that reliably tests for the presence of such antibodies.
This report presents a highly sensitive and speciﬁc neuronal
cell-based assay that provides sensitive and speciﬁc detection of
neutralizing antibodies to BoNT/A.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Botulinum neurotoxin (BoNT) produced by neurotoxigenic
clostridia are the most potent naturally occurring toxins
known [1]. Based on their antigenic speciﬁcity, BoNTs are dis-
tinguished into seven serotypes (A–G) [2], with BoNT/A, B
and E accounting for nearly all recorded cases of human bot-
ulism [1,3]. BoNTs are zinc-containing metalloproteases of ca.
150 kDa consisting of a heavy chain (100 kDa), and a light
chain (50 kDa) linked by a disulﬁde bond. The C-terminal
domain of the heavy chain functions in receptor binding on
the neuronal cell surface, inducing endocytotic internalization
of the toxin. Once inside the endosome, protonation causes
membrane insertion and chaperone/channel formation of the
heavy chain coupled to light chain unfolding and entry into
the channel. This is followed by light chain conduction
through the heavy chain channel and subsequent release of
the light chain by disulﬁde bond reduction and light chain
refolding in the cytoplasm of the cell [4,5]. Light chains of
BoNTs are zinc endopeptidases that target core proteins
including SNAP-25, VAMP/synaptobrevin, and syntaxin 1
involved in traﬃcking and release of neurotransmitters [6–11].*Corresponding author. Fax: +1 608 263 1114.
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doi:10.1016/j.febslet.2007.08.078The high potency of BoNT, its high speciﬁcity for motor neu-
rons, and the longevity of its action (up to several months) have
facilitated the use of BoNT/A and/B as extremely valuable
drugs for treatment of a myriad of neurological diseases, as well
as for cosmetic treatments, with BoNT/A being the most prom-
inent serotype currently used [12]. Despite the eﬀective use of
BoNTs in clinical applications, the major adverse eﬀect has
been the formation of antibodies which render patients refrac-
tory to treatment and tachyphylaxis [13–15]. For example, 5–
10% of patients with cervical, segmental or multifocal dystonia
receiving repeated BoNT/A treatments were estimated to devel-
op resistance to treatments due to the presence of circulating
neutralizing serum antibodies [14,15]. Resistance to BoNT
treatment can be conﬁrmed in a clinical setting by test injecting
BoNT into the patient’s frontalis muscle, extensor digitorum
brevis (EDB) or sternomastoid muscle [16–20], and measuring
compound muscle action potentials. However, patients are not
routinely monitored for antibody formation during their treat-
ment regime, since a sensitive assay that measures neutralizing
antibodies in human sera is not commercially available [21].
Such monitoring is highly desirable in clinical trials of BoNTs
as well as for currently approved therapies.
Several laboratory assays for the detection of BoNTs and
BoNT speciﬁc antibodies have been developed. The in vivo
mouse bioassay currently is the standard method to detect
BoNT activity, and the only assay approved by the FDA
[22,23]. In this assay, mice are injected intraperitoneally or
intravenously with toxin or toxin/antibody mixtures and
observed for signs of toxicity and death. While this assay is well
established and quantitative, it is relatively insensitive and has
well-known drawbacks including the need for a large number of
animals and associated required facilities and expenses, the
requirement for 2–4 days for results, non-speciﬁc deaths, and
the need to use mice.
Alternative in vitro assays include the mouse diaphragm
assay or MDA [22], enzyme-linked immunosorbent assays
(ELISAs) and variations, immunoprecipitation assay (IPA),
chemiluminescent slot blot immunoassay, electro chemilumin-
scence, radioimmunoassay, lateral ﬂow immunoassays, endo-
peptidase assays and others [25]. All of these assays can be
used to quantitate BoNT’s in vitro and in foods and clinical
samples [22,26–28]. However, many have the drawback of high
background, and most measure only one biological property of
BoNT activity (binding of the toxin to antibody, or proteolytic
activity in the endopeptidase assays). In order to reliably mea-
sure BoNT holotoxin activity and detect neutralizing serumblished by Elsevier B.V. All rights reserved.
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(i.e., binding of the heavy chain binding domain to the cell sur-
face receptor, endocytosis, channel formation, conductance of
the light chain into the cell’s cytosol and disulﬁde bond cleav-
age, refolding of the light chain, and proteolytic cleavage of the
target protein within the cell by the light chain).
A more complete approach for the screening of neutralizing
antibodies as well as potency determination of the holotoxin is
the use of cell-based BoNT assays. Several cell-based assays
have been developed, including continuous cell lines such as
neuro-2a, PC12, or SK-N-SH cells [8,29–31], as well as primary
neurons derived from chicken, mouse or rat spinal cord cells
[32–39]. Successful detection of BoNT can be achieved by Wes-
tern blot assay of the cleaved target protein [30,34–36,38], by
speciﬁc FRET sensors [29], or by neuronal activity testing
[31,33,37,39]. However, continuous cell lines exhibit very low
BoNT sensitivities and therefore cannot be used for detection
of serum antibodies. Most primary neuronal cell assays using
pure BoNT/A preparations have been reported to exhibit
sensitivities of approximately 50–100 pM of BoNT/A (250–
750 mouse LD50 U), which is not suﬃcient for detection of
most human serum antibodies. One primary cell assay has been
adapted to detect as little as 3 pM BoNT/A and protection by
up to 0.001 IU/ml of Equine International sera by measu-
ring [3H] glycine release from primary rat spinal cord cells
[33]. However, enhanced practicality and even higher sensitivity
and speciﬁcity are desired for clinical and research applications.
The assay presented here detects as little as 33 fM BoNT/A
and E (0.1 mouse LD50 U), and requires each step in the
intoxication process as it measures changes in intracellular
substrate cleavage and therefore all preceding steps of the
intoxication process must have already occurred. Using humanTable 1
Patient histories
Patient BoNT/A exposure and indication Response history
1 Over 12 injections for the
Treatment of Glabellar Wrinkles
(Botox)
Excellent result for 7 years
followed by complete loss of
2 Control Control
3 Essential blpeharsoapsm –
injections between 1989 and 1992
(50–100 U Botox)
Secondary none response in
Botox nor Dysport
4 Cervical dystonia – 16 injections
between 1992 and 1996
(200–300 U Botox)
Substantial Secondary reduc
5 Control Control
6 Control Control
7 Cervical dystonia 200–250 U of
Botox over 3 month intervals
1995–1998
Complete loss of response af
years to type A neurotoxin,
treated with type B
8 Cervical dystonia, receive eight
injections since 1991
Loss of response after 4 year
(secondary non-responder)
9 Cervical dystonia, treated with
200–300 U over 14 years
Retains an excellent sponse
10 Control Control
11 Vaccinated subject (three doses of
pentavalent vaccine in 1991–1992)
No response in remote point
12 Control Control
13 Cervical dystonia, eight injections
between 1991 and 1995
Response 50% reduced since
initiated (secondary reduced
responder)
14 Control Control
15 Essential blepharospasm Continues to have beneﬁt fro
repeated injectionsserum samples, the usefulness of the assay in detection of
neutralizing serum antibodies is presented and compared to
the mouse lethality assay.2. Materials and methods
2.1. Botulinum neurotoxin and mouse bioassay
Pure botulinum neurotoxin (BoNT) A, B, and E (150 kDa) were pre-
pared from Clostridium botulinum strains Hall A hyper, Okra B, and
Beluga E as previously described [40,41]. The toxins were dissolved
in phosphate buﬀered saline, pH 7.4 and 40% glycerol, and stored at
20 C until use. Activity of the BoNT/A,/B, and/E preparations were
determined by the mouse bioassay [22,23], and speciﬁc toxicity was
about 108 mouse LD50 U/mg.
To estimate the titer of serum samples by mouse lethality assay [33],
75 ll of serum were pre-incubated with 125 pg (and indicated dilu-
tions) of BoNT/A in a total volume of 0.3 ml for 1 h. Each dilution
was injected intraperintoneally into at least two mice, and the mice
were observed until death for up to 4 days.
2.2. Human sera samples
Human sera samples from patients repeatedly treated with
BOTOX who have demonstrated complete secondary resistance
(non-response), partial reduction in response, and continued eﬀective
responses were obtained from clinics after patient consent. An addi-
tional serum sample from a subject who received three doses of the
pentavalent vaccine 16 years ago was analyzed (#11). All sera were
stored at 20 C until use and subsequently at 4 C. Table 1 summa-
rizes the relevant medical histories of the patients. The sera were
labeled 1–15, and were used in a blinded manner.
2.3. Primary rat spinal cord (RSC) cells
The preparation of spinal cord cells was based on a previously de-
scribed protocol with modiﬁcations as described [42]. A pregnant Spra-
gue Dawley rat (Harlan Sprague–Dawley) at the gestational stage ofResults of remote point testing
(20 U)
Mouse bioassay
eﬀect
Frown lines not responsive Negative
Control Control
1993. No eﬀect on frontalis muscle
(positive for resistance)
Positive
ed response No eﬀect (positive for resistance) Positive
Control Control
Control Control
ter 3–4
now
No eﬀect (positive for resistance) Positive
s ND Positive
Sternomastoid shrinks with
injections
Negative
Control Control
test No eﬀect on frontalis muscle
in 2004
–
Control Control
No eﬀect or substantially reduced
eﬀect on frontalis muscle
ND
Control Control
m Frontalis muscle weak after
injection
Negative
Fig. 1. Diﬀerentiation of primary rat spinal cord cells over time. Cells
were plated onto collagen coated cover slips and observed by light
microscopy for up to 25 days after plating.
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S. Pellett et al. / FEBS Letters 581 (2007) 4803–4808 4805E15 was euthanized by exposure to CO2, and the uterus containing the
pups was removed and placed into a dish containing dissection med-
ium (Hanks balanced salt solution, 10 mM HEPES, 20 mM glucose
(Invitrogen)). Working in dissection medium, the pups were removed
from the uterus, immediately decapitated, the spinal cords were dis-
sected out of the pups, and the membranes and ganglia surrounding
the spinal cords were removed. The spinal cords were transferred to
4.4 ml of fresh dissection medium, minced, and transferred to a sterile
15 ml tube. Six-hundred millilitre of TrypLE express (Invitrogen) was
added, and trypsinization was allowed to take place for 20 min at
37 C in a 5% CO2 atmosphere. The trypsin solution was removed
and the spinal cords were washed once by addition of 15 ml of dissec-
tion medium. After the tissue settled to the bottom of the tube, the dis-
section medium was removed and 1 ml of culture medium pre-warmed
to 37 C (Neurobasal medium supplemented with B27, glutamax, and
penicillin/streptomycin (all from Invitrogen)) was added. The cells were
dissociated by pipetting up-and-down 10–12 times, and live cells were
counted by trypan exclusion assay. Cells (400000) were plated into each
well of collagen coated 24-well dishes (BD BioSciences). The cells were
allowed to diﬀerentiate in culture at 37 C in a humidiﬁed 5% CO2
atmosphere for at least 18 days with bi-weekly changes of culture med-
ium before they were used in the toxin assay. For microscopy, cells were
plated onto collagen coated cover slips (BD BioSciences).
2.4. Cell-based BoNT assay
After the diﬀerentiation period, various quantities of BoNT were
added to culture medium in a total volume of 300 ll per well, followed
by incubation at 37 C in a humidiﬁed 5% CO2 atmosphere for 48 h.
To test for serum antibody neutralization, 75 ll of serum (or dilutions
of serum in culture medium where indicated) were pre-incubated with
125 pg of BoNT/A (or as indicated) in a total volume of 300 ll per
sample at 37 C, 5% CO2 for 1 h prior to exposure of the cells. After
48 h, the cells were lysed in 150 ll of 1 · LDS lysis buﬀer (Invitrogen).
The samples were analyzed by SDS–PAGE gel electrophoresis on 12%
NuPAGE Novex Bis–Tris gels in NuPAGE MOPS running buﬀer
(Invitrogen), followed by transfer onto an Immobilon PVDF mem-
brane (Millipore). Full length and cleaved SNAP25 or VAMP were
detected with a monoclonal antibody to SNAP25 or VAMP1 (Synaptic
Systems) and the chemiluminescent Western Breeze kit (Invitrogen)
and exposure to X-ray ﬁlm (Kodak). To quantitate full length and
cleaved SNAP25 bands, the ﬁlms were scanned on a Gel DOC system
(BioRAD), and the bands were quantiﬁed by densitometry using
Quantity One software (BioRAD).30 kDa 
20 kDa 
40 kDa 
VAMP2
syntaxin
Fig. 2. Western blots showing BoNT sensitivity of RSC cells. RSC
cells were exposed to serial dilutions of BoNT/A (a), E (b), and B (c),
and cell lysates were examined by Western blot for SNAP25 (for A and
E) or VAMP (for B) cleavage.3. Results
3.1. BoNT sensitivity of RSC cells
In order to determine when the spinal cord cells were diﬀer-
entiated and ready and sensitive to BoNT, the cells were period-
ically examined by light microscopy at 5–25 days after plating
(Fig. 1). After 15 days, the appearance of cells did not change
signiﬁcantly, and no signiﬁcant change in BoNT/A sensitivity
was observed, even after 8 months (data not shown).
To determine BoNT sensitivity, RSC cells were exposed to
serial dilutions of BoNT/A, B, and E, incubated for 48 h,
and cleavage of the target protein (SNAP25 for BoNT/A
and E, and VAMP/synaptobrevin for BoNT/B) was examined
by Western blot. A weak band corresponding to the SNAP25
cleavage product was observed with as little as 1.5 pg of
BoNT/A or E (33 fM or approximately 0.1 mouse LD50 U),
and the relationship of cleaved versus full length SNAP25 with
increasing BoNT concentration was linear in the range of
6–125 pg BoNT/A and 12.5–125 pg BoNT/E. At 125 pg
BoNT/A (2.8 pM; ca. 10 mouse LD50 units), ca. 70–75% of
the SNAP25 was present in the cleaved form (Fig. 2a and b).
BoNT/B intoxication of the cells was determined by using an
antibody that recognizes only the full length VAMP/synapto-
brevin, but not the BoNT/B cleavage product (SynapticSystems) (Fig. 2c), and syntaxin as a loading control. A
decrease in the VAMP/synaptobrevin band was apparent at
250 pg BoNT/B (5.5 pM), and the band had almost completely
disappeared at 1 ng BoNT/B (22 pM).
3.2. Detection of neutralization of BoNT/A activity by human
sera in the RSC assay
To determine whether the assay correlated with clinical data
of BoNT/A resistance of patients, 15 human serum samples
were tested in a blinded manner. In this assay, 75 ll of the ser-
um samples were mixed with 125 pg of BoNT/A in a total vol-
ume of 0.3 ml, and the mixture was pre-incubated at 37 C for
1 h before exposure to the RSC cells.
In 5 of the 15 samples (#1, #4, #7, #11, and #13), no
SNAP25 cleavage product was detected on the Western blots,
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Fig. 3. Protection against SNAP25 cleavage in RSC cells by human
sera. RSC cells were exposed to A: a mixture of 125 pg BoNT/A and
25% human serum of 15 diﬀerent patients, and B: a mixture of 12.5 pg
BoNT/A and 25% of human serum #3 and #8, and the cell lysates were
assayed for SNAP25 cleavage by Western blot. The +C represents
toxin only controls and the C represents cells not treated with toxin
or serum.
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Fig. 4. Sensitivity of RSC cells for antibody detection. RSC cells were
exposed to a mixture of 125 pg BoNT/A and a (1) 1:200, (2) 1:400, (3)
1:800, (4) 1:1600, (5) 1:3200 dilution of human serum #4. A Western
blot of SNAP25 cleavage (a) and a quantitative representation of
densitometric analysis of three Western blots (b) are shown. The +C
represents 125 pg BoNT/A without serum, and the C contains no
toxin and no serum.
4806 S. Pellett et al. / FEBS Letters 581 (2007) 4803–4808indicating complete protection against BoNT/A induced
SNAP25 cleavage (Fig. 3). In two samples (#3 and #8), only
a small reduction in the ratio of cleaved versus full length
SNAP25 was observed, and this was conﬁrmed by repeating
the assay in triplicates (not shown). Additionally, in a repeat
RSC assay using only 12.5 pg of BoNT/A and 75 ll of serum
#3 and #8, nearly all full length SNAP25 was detected on
the Western blot, indicating protection against SNAP25 cleav-
age. No protection was observed using these two serum sam-
ples in an independently performed mouse lethality assay. In
all other samples, no signiﬁcant diﬀerence to the control (no
serum) was observed. These data were in excellent agreement
with clinical ﬁndings of resistance to BOTOX treatment
and remote point testing (see Table 1).
3.3. Determination of sensitivity of the RSC assay for antibody
detection
In order to determine the detection limit of this assay for neu-
tralizing serum antibodies, serial dilutions of serum #4 were
examined in the RSC assay in a blinded manner. Serum #4
was chosen because patient history indicated that it had the
highest titer and therefore allowed for analysis of the greatest
dilution range. In parallel, the serum was titered by mouse
lethality assay using the same amount of BoNT/A (125 pg or
ca. 10 LD50 U in 0.3 ml). The MLA was able to detect protec-
tion against BoNT/A induced death with serum dilutions of up
to 1:120 (50% of mice died). Higher dilutions resulted in death
of all mice tested (data not shown). One International Unit (IU)
can neutralize 104 mouse LD50 U of BoNT/A, therefore 0.3 ml
of this serum neutralizes 1200 U, and the titer of the serum was
estimated to be 0.4 IU/ml.
Using the RSC assay, signiﬁcant protection against cleavage
of SNAP25 was observed with serum dilutions of up to 1:1600.
The relationship of serum amount and SNAP25 cleavage was
linear within the range of serum dilutions of 1:200 and 1:3200,
with a Pearson coeﬃcient of 0.99 (Fig. 4). This indicates that
this assay can be used to reliably and quantitatively determine
the neutralizing BoNT/A antibody titers of human sera.
Based on these data, the titers of three serum samples were
determined using this assay. All three serum samples were
derived from patient #11 at diﬀerent times after a test injection
with 20 U of Botox, to which the patient was non-responsive.
The titer was similar in all three serum samples and was esti-mated at 0.006–0.0075 IU/ml by correlation to data from
dilutions of serum #4. An independently performed mouse
lethality assay conﬁrmed the titers of these samples (data not
shown).4. Discussion
The cell-based BoNT assay presented here is speciﬁc and
highly sensitive for BoNT/A, B, and E potency determination
(about 0.1 mouse LD50 U of BoNT/A and E), and is the most
sensitive assay reported in quantitative detection of neutraliz-
ing human serum antibodies to BoNTs. Compared to the
mouse bioassay/lethality assay, this assay has the following
advantages: (1) no need for large numbers of animals, (2) high-
er speciﬁcity due to the use of BoNT substrate cleavage as end-
point, (3) higher sensitivity in detection of neutralizing
antibodies, (4) excellent reproducibility with low standard
deviations, and (5) increased safety for laboratory workers as
toxin does not need to be handled in syringes. While this assay
still requires the use of relatively few animals in order to pre-
pare the primary spinal cord cells, one rat on average yields en-
ough cells for 72 assays, and a small number of replicas per
sample (3–5) are suﬃcient to yield reliable results. Currently,
the time required to complete the assay is approximately equal
to the mouse bioassay (3–4 days). Future reﬁnements of this
assay will determine optimal parameters such as toxin
concentration and preparation, number of replicas per sample,
incubation time, buﬀer composition, serum sampling and stor-
age.
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reported previously; however, they appear to either lack the
sensitivity required to be a valid replacement of the mouse bio-
assay, do not utilize a BoNT speciﬁc endpoint, or are imprac-
tical for routine testing [32,33,35–38]. It has been reported that
most sera of patient’s refractory to BoNT treatments have
titers in excess of 0.001 IU/ ml [24]; however, lower concentra-
tions still may have an impact on clinical response. Only one
assay previously reported is sensitive enough to detect
0.001 IU/ml [31]. However, it utilizes a non-BoNT speciﬁc end-
point (neurotransmitter release), and requires the use of radio-
isotopes. The assay described here utilizes a highly speciﬁc
endpoint (BoNT speciﬁc substrate cleavage), can reliably
quantify serum titers down to 0.0003 IU/ ml, and can detect
even lower levels by decreasing the quantity of toxin employed.
In fact, the sera of two patients examined contained titers too
low to be detected by the mouse lethality assay or by the RSC
assay using 125 pg of BoNT/A, however, the use of only
12.5 pg of BoNT/A resulted in the detection of neutralizing
antibodies (Fig. 3). These patients were resistant to BOTOX
treatments, although they had not received any treatments in
over 10 years. This emphasizes the clinical importance of
detecting very low antibody titers (below 0.001 IU/ml). The
ability to detect such low levels of antibodies may also prove
extremely useful in monitoring of patients for developing
BOTOX resistance.
Future studies are underway analyzing a larger number of
serum samples to further validate and reﬁne this assay. Even
though this assay currently has lower sensitivity for BoNT/B
(about 20 mouse LD50 U) and has not yet been tested in
BoNT/B antibody detection, the assay is likely adaptable to
BoNT/B antibody detection.
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